<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79056">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02062346</url>
  </required_header>
  <id_info>
    <org_study_id>Bean ICRF clinical study</org_study_id>
    <nct_id>NCT02062346</nct_id>
  </id_info>
  <brief_title>Endothelin Antagonism in ANCA Vasculitis</brief_title>
  <official_title>The Vascular Effects of Endothelin Receptor Antagonism in Systemic Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with vasculitis commonly develop high blood pressure (hypertension) and this is
      associated with an increased risk of heart disease. It is thus important to lower blood
      pressure in those with hypertension. However, hypertension in vasculitis is inadequately
      controlled with many currently available blood pressure lowering agents.

      Endothelin is a chemical produced by blood vessels that contributes to the development of
      hypertension. Higher than normal levels of endothelin are seen in patients with vasculitis.
      By using drugs that block the effects of endothelin ('endothelin receptor antagonists') the
      investigators can hopefully treat hypertension in patients with vasculitis. The purpose of
      the study is to ascertain whether endothelin receptor antagonists lower blood pressure and
      improve blood vessel function more effectively in patients with vasculitis than those
      without it.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vasculitis patients - matched for age, BP and renal function - will be recruited into 2
      groups defined by their induction immunosuppression: (i) CYC, (ii) MMF. A 3rd group will
      comprise control healthy subjects (n=10 for each). Subjects will attend for 4 study days &gt;1
      week apart. Circulating Mφ and other immune cells will be confirmed using FACS prior to each
      study. Day 1: assessment of vascular function. Days 2, 3 &amp; 4 (randomised &amp; infusions given
      in a double-blind method): comparison of the effects of selective ETA receptor antagonism
      (BQ123; 1000nmol/min for 15min iv), mixed ETA/B antagonism (BQ123/788; 1000 nmol/min &amp; 300
      nmol/min for 15 min), and placebo on systemic haemodynamics.

      Outcome measures

        -  Forearm blood flow

        -  tPA release

        -  Blood pressure

        -  Aix &amp; PWV
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>4h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response of participants to ET antagonism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forearm blood flow</measure>
    <time_frame>20min</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response to endothlium dependent and endothelium independent vasodilators</description>
  </secondary_outcome>
  <other_outcome>
    <measure>tPA release</measure>
    <time_frame>20min</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vasculitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BQ123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BQ123 1000nmol/min for 15min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BQ123/788</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BQ123 1000nmol/min; BQ788 300nmol/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Assessment of forearm vascular function</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Response of forearm blood flow to endothelium-dependent and endothelium-independent vasodilators</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ123 or BQ123/788</intervention_name>
    <arm_group_label>BQ123</arm_group_label>
    <arm_group_label>BQ123/788</arm_group_label>
    <other_name>Selective ETA or mixed ETA/B antagonism</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age 18-80

          -  Body mass index ≤35

          -  Normal serum albumin

        Exclusion Criteria:

          -  Subject is below the age of legal consent, or is mentally or legally incapacitated

          -  History of multiple and/or severe allergic reactions to drugs (including study
             drugs), or food

          -  The subject has donated blood (450 ml) within the last 4 weeks

          -  Past or present drug or alcohol abuse including intravenous drug abuse at any time

          -  Participation in another clinical trial within 1 month

          -  Considered to be at high risk of HIV or hepatitis B

          -  Women of child-bearing potential (only women who are post-menopausal or
             surgically-sterilised will be included in the study)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeraj Dhaun</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neeraj Dhaun, MD</last_name>
    <email>bean.dhaun@ed.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Midlothian</state>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neeraj Dhaun</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelin;</keyword>
  <keyword>blood pressure;</keyword>
  <keyword>vasculitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclo(Trp-Asp-Pro-Val-Leu)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
